EUVIMEDEUVIMED entdecken
Crossref

Cumulative exposure and cardiovascular risk: predictors of serious adverse outcomes following long-term intravenous lidocaine therapy for chronic pain

Natalie Shalit, Roy Shalit, Michelle Levitan iD, Hadas Afgin, Ofir Morag, Itay Goor-Aryeh

Pain Medicine · 2026

DOI: 10.1093/pm/pnag066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Medicine, 2026. Verfasst von Natalie Shalit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pain Medicine Institute, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Lidocaine, Chronic Pain, Cardiovascular Diseases, Anesthetics, Local. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous (IV) lidocaine has emerged as a non-opioid alternative for chronic pain management. However, the safety profile of repeated, long-term administration, particularly regarding cumulative exposure and cardiovascular comorbidities, remains poorly defined.

Objective

To identify risk factors for serious adverse outcomes (SAOs) following IV lidocaine infusion in chronic pain patients.

Methods

A retrospective cohort study examined 1093 patients treated with IV lidocaine at a hospital-based pain clinic in Israel (2014-2022), totaling 15 820 infusions. SAOs were defined as emergency department visits within 14 days of infusion. Multivariable logistic regression and Generalized Estimating Equations (GEE) were used to assess predictors, including cardiovascular disease, cerebrovascular accident (CVA) history, diabetes mellitus, and cumulative infusion count, to distinguish between true dose-frequency effects and artifacts of cumulative exposure time. A secondary analysis retained only events plausibly attributable to lidocaine based on its pharmacological profile.

Results

Fifty-five patients (5.0%) experienced SAOs. Cumulative exposure exceeding 50 infusions was the strongest predictor of adverse outcomes (OR = 12.58, P < .001). A GEE model accounting for repeated measures revealed that the risk per individual infusion remained stable and did not increase with the infusion sequence number (OR = 1.00, P = .854). CVA history was initially significant but lost significance in the secondary analysis when restricted to plausibly lidocaine-related events (n = 30), suggesting the association reflected disease progression rather than treatment effect. Conversely, pre-existing cardiovascular disease emerged as a significant predictor only in the refined analysis (OR = 3.88, P = .008), consistent with lidocaine’s known cardiac electrophysiological effects.

Conclusions

IV lidocaine demonstrates a favorable safety profile with low SAO incidence. While the statistical probability of an event increases with total exposure time, the per-infusion risk remains stable across the treatment course suggesting an absence of cumulative physiological toxicity. Pre-existing cardiovascular disease, specifically ischemic heart disease and arrhythmias, remains a primary risk factor. These findings support the use of enhanced cardiac monitoring for patients with these specific cardiovascular comorbidities and periodic risk-benefit reassessments for high-utilization patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LidocaineChronic PainCardiovascular DiseasesAnesthetics, LocalHumansRetrospective StudiesFemaleMaleMiddle AgedInfusions, IntravenousAgedRisk Factors

Stichwörter der Autor:innen

adverse outcomescardiovascular riskchronic painintravenous infusionlidocaine

Substanzen

LidocaineAnesthetics, Local

Autor:innen und Institutionen

  • Pain Medicine Institute, Sheba Medical Center, Ramat Gan, Israel.
  • The Dalia and David Arabov Endocrinology and Diabetes Research Center, Sheba Medical Center, Ramat Gan, Israel.
  • Endocrinology, Pain Medicine Institute, Sheba Medical Center, Ramat Gan, Israel.
  • Cancer Unit, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Michelle Levitan

Zitieren

APA

Shalit, N., Shalit, R., Levitan, M., Afgin, H., Morag, O., & Goor-Aryeh, I. (2026). Cumulative exposure and cardiovascular risk: predictors of serious adverse outcomes following long-term intravenous lidocaine therapy for chronic pain. Pain Medicine. https://doi.org/10.1093/pm/pnag066

Vancouver

Shalit N, Shalit R, Levitan M, Afgin H, Morag O, Goor-Aryeh I. Cumulative exposure and cardiovascular risk: predictors of serious adverse outcomes following long-term intravenous lidocaine therapy for chronic pain. Pain Medicine. 2026. doi:10.1093/pm/pnag066

BibTeX
@article{Shalit2026,
  author = {Shalit, Natalie and Shalit, Roy and Levitan, Michelle and Afgin, Hadas and Morag, Ofir and Goor-Aryeh, Itay},
  title = {Cumulative exposure and cardiovascular risk: predictors of serious adverse outcomes following long-term intravenous lidocaine therapy for chronic pain},
  journal = {Pain Medicine},
  year = {2026},
  doi = {10.1093/pm/pnag066}
}
Kostenlos starten →